| scholarly article | Q13442814 |
| P50 | author | Ming Guo | Q92493138 |
| P2093 | author name string | Jianping Wang | |
| Yun Gong | |||
| Roland L Bassett | |||
| Nour Sneige | |||
| Therese B Bevers | |||
| Abha Khanna | |||
| Genevieve R Lyons | |||
| Marilyn A Dawlett | |||
| Teresa L Kologinczak | |||
| P2860 | cites work | Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study | Q37135912 |
| Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines | Q39204728 | ||
| The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen | Q39362235 | ||
| Early detection of CIN3 and cervical cancer during long-term follow-up using HPV/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme. | Q42237593 | ||
| Cervical cancer rates after the transition from annual Pap to 3-year HPV and Pap. | Q42270834 | ||
| Follow-up outcomes of a large cohort of low-risk women with negative imaged liquid-based cytology and negative HPV test results | Q43465891 | ||
| Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance | Q45008006 | ||
| Increased cervical cancer risk associated with screening at longer intervals. | Q45977055 | ||
| American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer | Q57089342 | ||
| Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial | Q81404025 | ||
| Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial | Q82586477 | ||
| Image-guided ThinPrep Papanicolaou tests and cotesting with high-risk human papillomavirus in women aged 30 years and older in a low-risk private practice population | Q84475924 | ||
| Practice patterns in cervical cancer screening and human papillomavirus testing | Q84824464 | ||
| Human papillomavirus is a necessary cause of invasive cervical cancer worldwide | Q29617514 | ||
| Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test | Q30300975 | ||
| Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program. | Q30354591 | ||
| Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices | Q30487807 | ||
| Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test | Q33951517 | ||
| The 2001 Bethesda System: terminology for reporting results of cervical cytology | Q34124761 | ||
| Human papillomavirus and Papanicolaou tests to screen for cervical cancer | Q34702284 | ||
| American Cancer Society guideline for the early detection of cervical neoplasia and cancer | Q35018624 | ||
| Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening | Q35644704 | ||
| Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice | Q35738881 | ||
| Human papillomavirus testing 2007-2012: co-testing and triage utilization and impact on subsequent clinical management | Q36533952 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cervical intraepithelial neoplasia | Q196788 |
| P304 | page(s) | 644-651 | |
| P577 | publication date | 2017-05-12 | |
| P1433 | published in | Cancer Cytopathology | Q13452937 |
| P1476 | title | Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening | |
| P478 | volume | 125 |
| Q90558360 | Age-specific 3-year cumulative risk of cervical cancer and high-grade dysplasia on biopsy in 9434 women who underwent HPV cytology cotesting |
| Q59354820 | Dual staining for p16/Ki67 is a more specific test than cytology for triage of HPV-positive women |
| Q57165968 | How confident can we be in the current guidelines for exiting cervical screening? |
Search more.